Laia Crespo joined Sanofi Ventures in 2018 with a background in early-stage biotech investing and drug development. Prior to Sanofi, Laia served as Investment Director for Ysios Capital where she led investments and served on the board of multiple early-stage companies. Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech. Laia's active investments include Eligo Bioscience, Granite Bio, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, SpliceBio, T-Therapeutics and Therini Bio. Previous investments and board roles include Lava Therapeutics (LVTX). Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a Ph.D. with honors. Laia holds an M.B.A. from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.
BioTech
Direktes E-Mail-Muster
KI Outreach Agenten Pitch Writer
Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...